Controls pain in procedures involving the male and female urethra, for topical treatment…. ANDA 201094, held by Sagent Pharms Inc. Lidocaine Hydrochloride.
As of Nov 16, 2026, ANDA 201094 (Glydo), held by Sagent Pharms Inc, was first approved by FDA on Apr 28, 2014, with 1 approved supplement and 0 published complete response letters.
GLYDO 2% Jelly is indicated for prevention and control of pain in procedures involving the male and female urethra, for topical treatment of painful urethritis, and as an anesthetic lubricant for endotracheal intubation (oral and nasal).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 28, 2014 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Glydo2% · jelly;topical | Lidocaine Hydrochloride | Rx |
| Oct 29, 2019 | Supplement 6Labeling · Standard review | Approved | None posted |
| Apr 28, 2014 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters